Tokyo-based pharmaceutical company Astellas Pharma Inc., (TYO: 4503) has announced financial results for the first three quarters of its fiscal year 2023, ending December 31, 2023. The corporation reported a year-on-year (YOY) increase of 2.1% in global revenues, reaching JPY 1,189 billion (USD 8 billion) over the nine-month period.
Astellas’ key products demonstrated consistent growth, with the prostate cancer drug Xtandi (enzalutamide) leading the way at a 9.4% increase in sales to JPY 560 billion (USD 3.77 billion). The urothelial cancer therapy Padcev (enfortumab vedotin) exhibited a significant surge, with a 68.9% rise in revenue to JPY 55.6 billion (USD 370 million). Additionally, the acute myeloid leukemia (AML) drug Xospata (gilteritinib) also showed positive traction, with a 13.8% increase in sales to JPY 41.3 billion (USD 280 million). In the ophthalmology sector, the newly launched treatment Izervay (avacincaptad pegol) for geographic atrophy in the US has been well-received since its introduction.
Geographically, Astellas recorded its most substantial growth in International Markets, with a 14% increase to JPY 118.8 billion. This growth was followed by Established Markets, which includes Europe and Canada, showing a 12.5% expansion to JPY 272.2 billion. The Greater China region reflected a 3.3% growth, amounting to JPY 67.3 billion, while the US market experienced a slight decline of -3.9%, reporting revenues of JPY 481.4 billion.- Flcube.com
